Wells Fargo Upgrades Gilead Sciences to Overweight, Raises Price Target to $100
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo has upgraded Gilead Sciences from Equal-Weight to Overweight and increased its price target from $78 to $100, indicating a positive outlook on the company's stock.
October 07, 2024 | 4:28 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wells Fargo has upgraded Gilead Sciences to Overweight and raised its price target to $100, suggesting a positive short-term outlook for the stock.
The upgrade from Equal-Weight to Overweight by Wells Fargo, along with a significant increase in the price target, indicates a strong positive sentiment from the analyst. This is likely to boost investor confidence and could lead to a short-term increase in Gilead's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100